February 14, 2012 – Neurostimulation startup Neuros Medical, which is developing a device to block the chronic pain of amputees, has secured a new investor in RiverVest Venture Partners. Read More
ST. LOUIS, MO, Feb. 6, 2012, – RiverVest Venture Partners today announced that it successfully sold four life science companies for more than $1 billion, generated upfront returns of up to five times the initial investment, and beat industry benchmarks.
Investors in RiverVest Venture Partners are having a happy new year.
February 13, 2012 – St. Louis, MO – After selling four companies for a total of more than $1 billion in 2011, the Clayton-based venture capital firm in January made payments to investors of up to five times their original investment. Read More
ST. LOUIS, MO – RiverVest Venture Partners®, a venture capital firm investing in emerging medical technology and biopharmaceutical companies, today announced the promotion of Niall O’Donnell, Ph.D., to principal. Dr. O’Donnell joined RiverVest as a Kauffman Fellow in May 2006 and has continued his work as an associate since completing his fellowship in July 2008. His focus is biopharmaceutical, diagnostic and medical device opportunities.
ST. LOUIS, MO – RiverVest Venture Partners announced today that it has completed fundraising for its second fund, RiverVest Venture Fund II, L.P., with total committed capital of $75 million from private investors. RiverVest’s first fund, which was licensed as a Small Business Investment Company, had total private capital of $45 million,plus one tier of leverage from the Small Business Administration.
ST. LOUIS, MO and CLEVELAND, OH – RiverVest Venture Partners, a life science venture capital firm headquartered in St. Louis, MO, announced today that it will be opening an office at the BioEnterprise facility in Cleveland, OH. The office will be managed by Karen Spilizewski, who is joining RiverVest on a part-time basis as a vice president on January 1, 2008.
ST. LOUIS, MO – RiverVest Venture Partners®, a venture capital firm investing nationwide in emerging medical technology and biopharmaceutical companies, today announced that Gordon Foulkes, Ph.D., has joined the firm as a Venture Partner. Dr. Foulkes brings to RiverVest extensive operational experience in biopharmaceutical research and development.
ST. LOUIS, MO – RiverVest Venture Partners®, a venture capital firm investing nationwide in emerging medical technology and biopharmaceutical companies, has named Dennis Wahr, M.D., to the position of managing director. Wahr, a specialist in cardiac medicine, brings to the firm more than 25 years of experience in clinical practice and medical device entrepreneurship.
ST. LOUIS, MO – RiverVest Venture Partners, a national venture capital firm focusing on seed and early-stage life sciences investments, has named Scott R. Naisbitt, M.D., Ph.D. an associate and Floyd E. Bloom, M.D., a scientific advisor.
ST. LOUIS, MO – RiverVest Venture Partners announced today that the fundraising for RiverVest Venture Fund I, L.P. is complete, closing with $89 million of capital under management. The firm’s founders and managing directors are Andrew B. Craig III, Thomas C. Melzer, Jay W. Schmelter and Mark J. Mendel, Ph.D.